[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100253042":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":28,"responsibleParty":46,"collaborators":7,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":50,"sex":56,"minAge":57,"maxAge":7,"enrollmentInfo":58,"targetDuration":7,"studyType":61,"phases":7,"briefSummary":62,"conditions":63,"keywords":7,"overallStatus":31,"whyStopped":7,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"PROCEDURE","Local biopsy in the tumor","A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.",[14],{"name":15,"affiliation":5,"role":16},"Jean-Pascal Machiels, MD, PhD","PRINCIPAL_INVESTIGATOR",[18,24],{"name":19,"role":20,"phone":21,"phoneExt":22,"email":23},"Aline Gillain, MedSciences","CONTACT","00322764","5498","aline.gillain@uclouvain.be",{"name":25,"role":20,"phone":21,"phoneExt":26,"email":27},"Sandra Schmitz, MD, PhD","5470","sandra.schmitz@uclouvain.be",[29],{"facility":30,"status":31,"city":32,"state":7,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Cliniques universitaires Saint-Luc","RECRUITING","Brussels","1200","Belgium","BE",{"type":37,"coordinates":38},"Point",[39,40],4.34878,50.85045,{"lat":40,"lon":39},[43,45],{"name":15,"role":20,"phone":7,"phoneExt":7,"email":44},"jean-pascal.machiels@uclouvain.be",{"name":19,"role":20,"phone":7,"phoneExt":7,"email":23},{"type":47,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100253042","patient-derived-xenograft-models-of-tumor-from-patients-with-head-and-neck-cancer-100253042",false,"NCT02572778","Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer","Establishment of Primary Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer for Preclinical Evaluation of Targeted Therapies.","UCL-Xenog","Inclusion Criteria:\n\n* In the first phase, all patients with primary or recurrent\u002F metastatic disease of head and neck cancer can be included pre-operatively or before a tumor biopsy after obtaining informed consent\n* Data on stage, grade, histology, adjuvant treatment, responses, relapse should be available\n* Follow-up data should be available\n* Patients with recurrent disease are allowed\n* Written informed consent","ALL","18 Years",{"count":59,"type":60},40,"ESTIMATED","OBSERVATIONAL","The investigators want to have a collection of fresh primary or recurrent tumor tissue for establishment of patients-derived xenografts in order to:\n\ngenerate a biobank of in vivo patient xenografts representing the different subgroups of tumors for head and neck cancer\n\n* perform genetic and transcriptional profiling of the primary, metastatic tumors and xenograft tumors\n* evaluate the efficacy of new targeted agents, whether or not in combination with standard treatment options\n* evaluate biomarkers of drug sensitivity\n* study primary and secondary (acquired) resistance in these models",[64],"Squamous Cell Carcinoma of the Head and Neck","2024-12-02",{"date":67,"type":68},"2024-12-03","ACTUAL",{"date":70,"type":68},"2015-09",{"date":72,"type":60},"2025-12",{"name":5,"class":6},1]